Fig. 7: ACT-DC in combination with anti-PD1 antibody induces anti-tumor immune response in an orthotopic CT-2A glioma model.

a Schedule of the therapeutic study in the CT-2A model. Created in BioRender. Zhao, Z. (2025) https://BioRender.com/3ow34vf. b Survival curves of mice treated with different formulations. c–e Tumor-infiltrating lymphocyte (TIL) and tumor-associated myeloid cell (TAMC) in the brains of mice 100 days after tumor inoculation. c Representative flow cytometry plots of TIL and TAMC. d Quantification of the abundance of TIL and TAMC. e Relative ratio of TIL to TAMC in the brain. f–h CD4 and CD8 T cells in the brain of mice 100 days after tumor inoculation. f Representative flow cytometry plots of CD4 and CD8 T cells. g, h Percentage of CD8 T cells (g) and CD4 T cells (h) in CD45⁺ cells in the brain. i–k T helper CD4 T cells and Tregs in the brain of mice 100 days after tumor inoculation. i Representative flow cytometry plots. j Percentage of T helper CD4 T cells and Tregs. k Relative ratio of T helper cells to Tregs. For c–k, “Non-tumor” refers to healthy mice without tumor implantation. “Tumor” refers to mice inoculated with CT-2A tumors for 21 days. “LTS (long-term survivor)” refers to mice that received RT + ACT-DC+aPD1 treatments and survived on day 100 after tumor inoculation. For d, e, g,h, j, k, data were presented as mean values ± SEM. For b, n = 6 for the RT + ACT-DC+aPD1 group, n = 7 for the other groups, biologically independent mice. For c–k, n = 3 for the LTS group, n = 5 for the “Tumor” and “Non-tumor” groups, biologically independent mice. For b, statistical analysis was performed using two-sided Mantel–Cox tests. Statistical analysis for (d, e, g, h): one-way ANOVA followed by Dunnett test. Statistical analysis for (j, k): two-tailed unpaired Student’s t-test. Source data are provided as a Source Data file.